Youngkyu Shim

Youngkyu Shim

Auto-generated profile, based on publicly available information

Youngkyu Shim

Allergy Immunology Center, Korea University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
YSYoungkyu Shim
Youngkyu Shim
SKSoo Yeon Kim
Soo Yeon Kim
HKHunmin Kim
Hunmin Kim
HHHee Hwang
Hee Hwang
JCJong-Hee Chae
Jong-Hee Chae
BLByung Chan Lim
Byung Chan Lim

1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
IYILHAN YOO
ILHAN YOO
WKWooJoong Kim
WooJoong Kim
YSYoungkyu Shim
Youngkyu Shim
SCSun Ah Choi
Sun Ah Choi
SKSoo Yeon Kim
Soo Yeon Kim
JCJong-Hee Chae
Jong-Hee Chae
Yoo IH, et al. J Clin Neurol. 2020 Jul;16(3):461-469. https://doi.org/10.3988/jcn.2020.16.3.461

1 October 2020 in Annals of Child Neurology
Verified
Journal Article
Open access
PDF file
YSYoungkyu Shim
Youngkyu Shim
YGYoung Jun Go
Young Jun Go
SKSoo Yeon Kim
Soo Yeon Kim
HKHunmin Kim
Hunmin Kim
HHHee Hwang
Hee Hwang
JCJong-Hee Chae
Jong-Hee Chae

1 January 2021 in Pediatric Infection & Vaccine
Verified
Journal Article
Open access
PDF file
KPKyu Hyun Park
Kyu Hyun Park
YCYoung June Choe
Young June Choe
YSYoungkyu Shim
Youngkyu Shim
BEBaik-Lin Eun
Baik-Lin Eun
JBJUNGHYE BYEON
JUNGHYE BYEON
Park KH, et al. Pediatr Infect Vaccine. 2021 Dec;28(3):144-148. https://doi.org/10.14776/piv.2021.28.e20

1 July 2025 in Epilepsy & Behavior
Verified
Journal Article
Closed access
YSYoungkyu Shim
Youngkyu Shim
WKWoo Joong Kim
Woo Joong Kim
HKHunmin Kim
Hunmin Kim
JCJaeso Cho
Jaeso Cho
JCJong Hee Chae
Jong Hee Chae
BLByung Chan Lim
Byung Chan Lim

30 January 2026 in Medicine
Verified
Journal Article
Open access
YSYoungkyu Shim
Youngkyu Shim
DYDong Hwa Yang
Dong Hwa Yang
JBJUNGHYE BYEON
JUNGHYE BYEON
BEBaik-Lin Eun
Baik-Lin Eun
This retrospective cohort study evaluated the tolerability, efficacy, and safety of adjunctive cannabidiol (CBD) therapy in pediatric-onset intractable epilepsy across diverse genetic and nongenetic etiologies. Twenty-nine patients aged 6 to 24 years, treated at Korea University Hospitals between April 2019 and May 2024, were included. The median follow-up duration was 14.3 months. Confirmed genetic etiologies included SCN1A -related epilepsy (6.9%); GABRB3 -, SCN2A -, KCNT1 -, KIF1A -, and COL4A1 -related epilepsies (3.4% each); Angelman syndrome and Down syndrome (3.4% each). Presumed genetic etiologies included hemimegalencephaly (3.4%) and cortical dysplasia (6.9%). Acquired causes included hypoxic brain injury (6.9%) and CNS infection (10.3%). In 41.4% of cases, the etiology was unidentified; among them, 58.3% had a history of infantile spasms. At CBD initiation, patients were receiving a median of 5 antiseizure medications, most commonly valproic acid (93.1%), clobazam (82.8%), and levetiracetam (75.9%). The median maintenance dose of CBD was 14.2 mg/kg/d. The retention rate was above 86% at both 12 and 24 months. At 12 months, 79.3% achieved a ≥50% reduction in seizure frequency, and 34.5% achieved a ≥75% reduction without generalized motor seizures. One patient with a GABRB3 variant achieved seizure freedom. Adverse events occurred in 37.9%, most commonly somnolence and lethargy. These were mild and resolved with antiseizure medication adjustments. CBD was discontinued in 3 patients due to pneumonia, lethargy, or seizure aggravation. CBD therapy demonstrated favorable retention, efficacy, and safety profiles in pediatric-onset intractable epilepsy across a spectrum of etiologies.